Lexicon Pharmaceuticals, Inc. (LXRX) Financials
LXRX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 276.5 million | 137.0 million |
2023-06-30 | 316.7 million | 130.4 million |
2023-03-31 | 162.7 million | 74.7 million |
2022-12-31 | 194.3 million | 77.2 million |
LXRX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -41.7 million | 3.9 million |
2023-06-30 | -38.3 million | 3.8 million |
2023-03-31 | -31.9 million | 3.4 million |
2022-12-31 | -22.8 million | 3.3 million |
LXRX Net Income
No data available :(
LXRX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 218.4 million | - | 6.7 million |
2023-06-30 | 256.7 million | - | 6.8 million |
2023-03-31 | 105.9 million | 48.8 million | 6.7 million |
2022-12-31 | 138.4 million | - | 6.7 million |
LXRX Shares Outstanding
LXRX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | 83000 | 17.6 million | 2.6 million | 29.7 million |
2023-06-30 | 139000 | 14.5 million | 30.0 million | 27.5 million |
2023-03-31 | 248000 | 12.0 million | 2.2 million | 16.9 million |
2022-12-31 | 1.2 million | 14.0 million | 10.7 million | 5.6 million |
LXRX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 162000 | 7000 |
2023-06-30 | 317000 | 8000 |
2023-03-31 | 24000 | 112000 |
2022-12-31 | 28000 | 103000 |
LXRX
Price: $1.58
52 week price:
Earnings Per Share: -0.80 USD
P/E Ratio: -4.38
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 131023
Ebitda: -28.2 millionMarket Capitalization: 460.5 million